Clinical Cardiology Alert – September 1, 2014
September 1, 2014
View Issues
-
Is Left Atrial Appendage Occlusion with the Watchman Device a Reasonable Alternative to Anticoagulation with Warfarin?
The goal of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy (PREVAIL) trial was to assess the safety and efficacy of left atrial appendage (LAA) occlusion for stroke prevention in patients with atrial fibrillation (AF) compared with long-term warfarin therapy -
Is Less More? Transfemoral TAVR: The Minimalist Approach
Since its initial FDA approval in November 2011, transcatheter aortic valve replacement (TAVR) has rapidly gained acceptance as a standard therapy in the United States. -
Colchicine for Recurrent Pericarditis
Although colchicine has been shown to be effective for the treatment of acute pericarditis and first recurrences, little information exists about its use in patients with multiple recurrences. Thus, Imazio et al reported on the results of the colchicine for recurrent pericarditis 2 (CORP-2) trial. -
Angiotensin Receptor Blockers for Hypertension
Angiotensin receptor blockers (ARBs) are often used as first-line therapy for the treatment of systemic hypertension because of their perceived efficacy and relatively low incidence of adverse effects. -
Bioabsorbable Coronary Scaffolds: Promise and Peril
Clinical outcomes from percutaneous coronary intervention (PCI) have steadily improved over time, with transitions from balloon angioplasty to bare-metal stenting, and more recently from first-generation drug-eluting stents (DES) to second- and third-generation designs. -
Pharmacology Watch and Clinical Briefs in Primary Care Available Online
The September 2014 issues of Pharmacology Watch and Clinical Briefs in Primary Care are now available exclusively by e-mail or online.